Clinical and laboratory features of autoimmune hemolytic anemia associated with immune checkpoint inhibitors

American Journal of Hematology
Rebecca Karp LeafDavid E Leaf

Abstract

Immune checkpoint inhibitors (ICPis) are a novel class of immunotherapeutic agents that have revolutionized the treatment of cancer; however, these drugs can also cause a unique spectrum of autoimmune toxicity. Autoimmune hemolytic anemia (AIHA) is a rare, but often severe, complication of ICPis. We identified 14 patients from nine institutions across the United States who developed ICPi-AIHA. The median interval from ICPi initiation to development of AIHA was 55 days (interquartile range [IQR], 22-110 days). Results from the direct antiglobulin test (DAT) were available for 13 of 14 patients: 8 patients (62%) had a positive DAT and 5 (38%) had a negative DAT. The median pretreatment and nadir hemoglobin concentrations were 11.8 g/dL (IQR, 10.2-12.9 g/dL) and 6.3 g/dL (IQR, 6.1-8.0 g/dL), respectively. Four patients (29%) had a preexisting lymphoproliferative disorder, and two (14%) had a positive DAT prior to initiation of ICPi therapy. All patients were treated with glucocorticoids, with three requiring additional immunosuppressive therapy. Complete and partial recoveries of hemoglobin were achieved in 12 (86%) and 2 (14%) patients, respectively. Seven patients (50%) were rechallenged with ICPis, and one (14%) developed recur...Continue Reading

References

Jul 26, 2005·Seminars in Hematology·John W Semple, John Freedman
Apr 1, 2009·Proceedings of the National Academy of Sciences of the United States of America·Xin HuangAlfred Ayala
Dec 17, 2009·Hematology·George Garratty
Jul 27, 2010·Transfusion Medicine Reviews·Melca M O BarrosJosé O Bordin
Jun 1, 2011·The Journal of Experimental Medicine·Erin E ZollerMichael B Jordan
Jan 15, 2014·Blood Cells, Molecules & Diseases·George B Segel, Marshall A Lichtman
Feb 14, 2014·Frontiers in Physiology·Djuna Z de BackRobin van Bruggen
Jul 6, 2014·Journal of Medical Case Reports·Ester SimeonePaolo Antonio Ascierto
Jan 22, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michael A PostowJedd D Wolchok
Dec 24, 2015·Transfusion Medicine and Hemotherapy : Offizielles Organ Der Deutschen Gesellschaft Fur̈ Transfusionsmedizin Und Immunham̈atologie·Wilma Barcellini
Jan 23, 2016·Melanoma Research·Benjamin Y KongMatteo S Carlino
Mar 18, 2016·The New England Journal of Medicine·Ranjit NairSuresh G Nair
Jun 11, 2016·Kidney International·Frank B CortazarDavid E Leaf
Nov 3, 2016·The New England Journal of Medicine·Douglas B JohnsonJavid J Moslehi
Dec 7, 2016·Case Reports in Oncology·Amruth R PallaDonald Doll
Dec 23, 2016·British Journal of Haematology·Quentin A HillUNKNOWN British Society for Haematology
Feb 24, 2017·American Journal of Hematology·Rebecca Karp LeafReed E Drews
Feb 28, 2017·Journal for Immunotherapy of Cancer·Eileen ShiuanDouglas Johnson
Feb 28, 2017·Journal for Immunotherapy of Cancer·Uqba KhanTarik Hadid
Apr 1, 2017·Blood·Ronald S GoNeil E Kay
Apr 12, 2017·Klinická onkologie : casopis Ceské a Slovenské onkologické spolecnosti·B RamosR K Rovere
Jun 25, 2017·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Sébastien Le BurelOlivier Lambotte
Nov 8, 2017·Journal of Immunotherapy·Yamin SunCristhiam M Rojas-Hernandez
Jan 11, 2018·The New England Journal of Medicine·Michael A PostowMatthew D Hellmann
Feb 11, 2018·Journal of Hepatology·Eleonora De MartinDidier Samuel
Feb 15, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Julie R BrahmerUNKNOWN National Comprehensive Cancer Network
Mar 15, 2018·Lancet·Javid J MoslehiDouglas B Johnson
Mar 24, 2018·Journal of the American College of Cardiology·Syed S MahmoodTomas G Neilan
Apr 20, 2018·BMJ Case Reports·Hira ShaikhSalman Fazal
May 16, 2018·Journal of Neurology·Sarah ManconeRoy E Strowd
Jun 12, 2018·Anti-cancer Drugs·Ariane BarbackiDavid Small
Aug 4, 2018·Blood Advances·Merve HasanovCristhiam M Rojas Hernandez
Oct 24, 2018·Journal for Immunotherapy of Cancer·Jaqueline GhosnMichel Obeid
Dec 7, 2018·Hematology·Anita Hill, Quentin A Hill
Jan 12, 2019·Case Reports in Otolaryngology·James H KimBozena Barbara Wrobel

❮ Previous
Next ❯

Citations

Apr 11, 2020·Expert Review of Hematology·Wilma BarcelliniBruno Fattizzo
Apr 4, 2020·American Journal of Hematology·Steven R HwangAlexandra P Wolanskyj-Spinner
Jul 14, 2020·Frontiers in Immunology·Wilma Barcellini, Bruno Fattizzo
Apr 8, 2020·BMJ : British Medical Journal·Karmela K Chan, Anne R Bass
Sep 22, 2020·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Christina M YounceDhimant R Patel
Dec 8, 2019·BMJ Case Reports·Harriet Williams, Robin Aitchison
Dec 3, 2020·Journal of Clinical Medicine·Wilma BarcelliniBruno Fattizzo
Dec 3, 2020·Journal of Clinical Medicine·Bruno FattizzoWilma Barcellini
Mar 12, 2021·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Rafaela KramerLucie Heinzerling
May 27, 2021·Med·Joanna RoopkumarAlok A Khorana
Jul 29, 2021·Nature Reviews. Drug Discovery·Ryan J Sullivan, Jeffrey S Weber
Aug 28, 2021·The American Journal of Emergency Medicine·Michael J YooMichael Gottlieb
Sep 2, 2021·Journal of Immunotherapy·Nathaniel R WilsonCristhiam M Rojas-Hernandez

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Hemolytic Anemia

Autoimmune hemolytic anemia (AIHA) occurs when antibodies directed against the person's own red blood cells (RBCs) cause them to burst (lyse), leading to an insufficient number of oxygen-carrying red blood cells in the circulation. Discover the latest research on AIHA here.

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.

Autoimmune Lymphoproliferative Syndrome

Autoimmune lymphoproliferative syndrome (ALPS) is a rare genetic disorder of abnormal lymphocyte survival caused by defective Fas mediated apoptosis. Discover the latest research on ALPS here.

Related Papers

The American Journal of Pediatric Hematology/oncology
A Kowal-VernJ Blank
Beiträge zur Infusionstherapie = Contributions to infusion therapy
G Garratty
© 2022 Meta ULC. All rights reserved